Diagnosing mental illnesses, such as schizophrenia, has long been difficult and controversial. Since physical evidence of the condition can only be gathered from the brain post-mortem, mental health professionals have had to rely on a battery of psychological evaluations and “symptoms” to diagnose their patients.
A recent study from Tel Aviv University may now prove to be a significant breakthrough in diagnosing the condition. By collecting tissue from the nose through a simple biopsy, researchers have actually been able to diagnose the condition in a “more sure-fire” way than ever before, according to lead researcher Dr. Noam Shomron.
Get our weekly highlights directly in your inbox!Sign up
This finding, which was reported in the journal Neurobiology of Disease, could not only lead to a more accurate diagnosis, it may also lead to the crucial, early detection of the disease, giving rise to vastly improved treatment overall.
Samples of olfactory neurons from patients diagnosed with schizophrenia
Until now, biomarkers for schizophrenia had only been found in the neuron cells of the brain, which can’t be collected before death. By that point it’s obviously too late to do the patient any good, says Shomron. Instead, psychiatrists depend on psychological evaluations for diagnosis, including interviews with the patient and reports by family and friends.
For a solution to this diagnostic dilemma, the researchers turned to the olfactory system, which includes neurons located on the upper part of the inner nose. Researchers at Johns Hopkins University collected samples of olfactory neurons from patients diagnosed with schizophrenia and a control group of non-affected individuals, then sent them to Shomron’s TAU lab.
- Facebook Causes ‘Psychotic Episodes and Delusions’, Study Claims
- Israeli Team Heads Research Into ‘Electronic Nose’ To Sniff Out Cancer
Shomron and his fellow researchers applied a high-throughput technology to these samples, studying the microRNA of the olfactory neurons. Within these molecules, which help to regulate our genetic code, they were able to identify a microRNA which is highly elevated in people with schizophrenia, compared to individuals who do not have the disease.
“We were able to narrow down the microRNA to a differentially expressed set, and from there down to a specific microRNA which is elevated in individuals with the disease compared to healthy individuals,” Shomron explains. Further research revealed that this particular microRNA controls genes associated with the generation of neurons.
Early detection – early treatment
In practice, material for biopsy could be collected through a quick and easy outpatient procedure, using a local anesthetic, says Shomron. And with microRNA profiling results ready in a matter of hours, this method could evolve into a relatively simple and accurate test to diagnose a very complicated illness.
Dr. Shomron concedes there is still much more to investigate, including whether this alteration in microRNA expression begins before schizophrenic symptoms start to exhibit themselves, or only after the disease fully develops, he says. If this change comes near the beginning of the timeline, it could be invaluable for early diagnostics. This would mean early intervention, better treatment, and possibly even the postponement of symptoms, he says.
If a person has a family history of schizophrenia, this test could reveal whether they too suffer from the disease, Shomron adds. And while such advanced warning does not mean a cure is on the horizon, it will help both patient and doctor identify and prepare for the challenges ahead.
The research was conducted by Shomron and Prof. Ruth Navon of Tel Aviv University’s Sackler Faculty of Medicine, together with PhD student Eyal Mor from Dr. Shomron’s lab and Prof. Akira Sawa of Johns Hopkins Hospital in Baltimore, Maryland
Photo: Tel Aviv University